Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma Cells

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Bu, Xinxin ^a   Jia, Fengqi ^a   Wang, Weifeng ^a   Guo, Xianling ^a   Wu, Mengchao ^a   Wei, Lixin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; RISK FACTOR; SILVER STAINING; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; WESTERN BLOTTING; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; LIVER NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TELOMERASE; TRANSCRIPTION, GENETIC;

EID: 38049112379     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-208     Document Type: Article

References (40)

1. El-Serag HB: Hepatocellular Carcinoma: An Epidemiologic View. Journal of Clinical Gastroenterology 2002, 35(5 Suppl 2):S72-78. 10.1097/ 00004836-200211002-00002 12394209
2. Blume-Jensen P Hunter T: Oncogenic kinase signaling. Nature 2001, 411(6835):355-365. 10.1038/35077225 11357143
3. Datta SR Brunet A Greenberg ME: Cellular survival:a play in three Akts. Genes Dev 1999, 13:2905-2927. 10.1101/gad.13.22.2905 10579998
4. Brown EJ Albers MW Shin TB Ocjlawa K Keith CT Lane WS Schreiber SL: A mammalian protein targeted by G1-arresting rapamycin receptor complex. Nature 1994, 369(6483):756-758. 10.1038/369756a0 8008069
5. Chiu MI Katz H Berlin V: RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci 1994, 91(26):12574-12578. 45481 7809080 10.1073/pnas.91.26.12574
6. Sabatini DM ErdjumenA-Bromage H Liu M: Tempst P Snyder SH RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994, 78(1):35-43. 10.1016/ 0092-8674(94)90570-3 7518356
7. Brown EJ Beal PA Keith CT Chen J Shin TB Schreiber SL: Control of p70s6 kinase activity of FRAP in vivo. Nature 1995, 377(6548):441-446. 10.1038/ 377441a0 7566123
8. Burnett PE Barrow RK Cohen NA Snyder SH Sabatini DM; RAFT1 phosphorylation of the translational regulators p70s6 kinase and 4E-BP1. Proc Natl Acad Sci 1998, 95(4):1432-1437. 19032 9465032 10.1073/ pnas.95.4.1432
9. Isotani S Hara K Tokunaga C Inoue H Avruch J Yonezawa K: Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem 1999, 274(48):34493-34498. 10.1074/ jbc.274.48.34493 10567431
10. Jefferies HB Fumagalli S Dennis PB Reinhard C Pearson RB Thomas G: Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997, 16(12):3693-3704. 1169993 9218810 10.1093/emboj/ 16.12.3693
11. Jefferies HB Reinhard C Kozma SC Thomas G Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family Proc Natl Acad Sci 1994 91 10 4441 4445 43801 8183928 10.1073/ pnas.91.10.4441
12. Lawrence JC Jr Abraham RT: PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trends Biochem Sci 1997, 22(9):345-349. 10.1016/ S0968-0004(97)01101-8 9301335
13. Rousseau D Gingras AC Pause A Sonenberg N: The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996, 13(11):2415-2420. 8957083
14. Shi Y Yan H Frost P Gera J Lichtenstein A: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005, 4(10):1533-1540. 10.1158/1535-7163.MCT-05-0068 16227402
15. Shi Y Frankel A Radvanyi LG Penn LZ Miller RG Mills GB: Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995, 55(9):1982-1988. 7728769
16. Terada N Patel HR Takase K Kohno K Nairn AC Gelfand EW: Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci 1994, 91(24):11477-11481. 45254 7972087 10.1073/pnas.91.24.11477
17. Nielsen FC Ostergaard L Nielsen J Christiansen J; Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway. Nature 1995, 377(6547):358-362. 10.1038/377358a0 7566093
18. Rosenwald IB Kaspar R Rousseau D Gehrke L Lebulch P Chen JJ Schmidt EV Sonenberg N London IM: Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995, 270(36):21176-21180. 10.1074/jbc.270.36.21176 7673150
19. Castedo M Ferri KF Kroemer G: MaRmalian target of rapamycin (mTOR):pro- and anti-apoptotic. Cell Death Differ 2002, 9(2):99-100. 10.1038/sj/cdd/ 4400978 11840159
20. Muller M Heicappell R Krause H Sachsinger J Porsche C Miller K: Telomerase activity in malignant and benign renal tumors. Eur Urol 1999, 35(3):249-257. 10.1159/000019856 10072629
21. Counter CM Meyerson M Eaton EN Ellison LW Caddle SD Haber DA Weiberg RA: Telomerase activity is restored in human cells by ectopic expression of hTERT(hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16(9):1217-1221. 10.1038/sj.onc.1201882 9528864
22. Mehle C Piatyszek MA Ljungberg B Shay JW Roos G: Telomerase activity in human renal cell carcinoma. Oncogene 1996, 13(1):161-166. 8700542
23. Morin GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989, 59(3):521-529. 10.1016/0092-8674(89)90035-4 2805070
24. Counter CM Hirte HW Bachetti S Harley CB: Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci 1994, 91(8):2900-2904. 43481 8159676 10.1073/pnas.91.8.2900
25. Kim NW Piatyszek MA Prowse KR Harley CB West MD Ho PL Coviello GM Wright WE Weinrich SL Shay JW: Specific association of human telomerase activity with immortal cells and cancers. Science 1994, 266(5193):2011-2015. 10.1126/science.7605428 7605428
26. Shay JW Bachetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33(5):787-791. 10.1016/S0959-8049(97)00062-2 9282118
27. Nagao K Tomimatsu M Endo H Hisatomi H Hikiji K: Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol 1999, 34(1):83-87. 10.1007/s005350050220 10204615
28. Gerelsaikhan T Tavis JE Bruss V Hepatisis B: Virus nucleocapsid development does not occur without genomic DNA synthesis. J Virol 1996, 70(7):4269-4274. 190358 8676448
29. Gorbunova V Seluanov A; Telomerase as a growth-promotingfactor. Cell Cycle 2003, 2(6):534-537. 14504469
30. Saretzki G: Telomerase inhibition as cancer therapy. Cancer Lett 2003, 194(2):209-219. 10.1016/S0304-3835(02)00708-5 12757979
31. Abraham RT: Identification of TOR sigMaling complexes: more TORC for the cell growth engine. Cell 111(1):9-12. 10.1016/S0092-8674(02)01009-7 12372295
32. Erbay E Chen J: The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J Biol Chem 2002, 276(39):36079-36082. 10.1074/jbc.C100406200
33. Shu L Zhang X Houghton PJ: Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem 2002, 277(19):16726-16732. 10.1074/jbc.M112285200 11875068
34. Jacinto E Hall MN: Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003, 4(2):117-126. 10.1038/nrm1018 12563289
35. Braun-Dullaeus RC Mann MJ Seay U Zhang L von Der Leyen HE Morris RE Dzau VJ: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001, 21(7):1152-1158. 10.1161/hq0701.092104 11451744
36. Guba M von Breitenbuch P Steinbauer M Koehl G Flegel S Hornung M Bruns CJ Zuelke C Farkas S Anthuber M Jauch KW Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002, 8(2):128-135. 10.1038/ nm0202-128 11821896
37. Choi JH Bertram PG Drenan R Carvalho J Zhou HH Zheng XF: The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase. EMBO Rep 2002, 3(10):988-994. 1307618 12231510 10.1093/embo-reports/kvf197
38. Houghton PJ Huang S: MTOR as a target for cancer therapy. Curr Top Microbiol Immunol 2004, 279:339-359. 14560967
39. Gingras AC Raught B Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 2002, 15(7):807-826. 10.1101/gad.887201
40. Huang S Houghton PJ: Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr Opin Investig Drugs 2002, 3(2):295-304. 12020063